This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Reviparin
- DrugBank Accession Number
- DB09259
- Background
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.1 It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.2 It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.3
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Synonyms
- Reviparin sodium
Pharmacology
- Indication
By the FDA, reviparin is indicated for the treatment of deep vein which may lead to pulmonary embolism in pediatric patients. It is also indicated for the long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients.3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Reviparin is been shown to present significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth.1
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Reviparin. Acebutolol The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Reviparin. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Reviparin. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Reviparin. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Reviparin. Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Reviparin. Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Reviparin. Aldesleukin The risk or severity of bleeding can be increased when Reviparin is combined with Aldesleukin. Alemtuzumab The risk or severity of bleeding can be increased when Reviparin is combined with Alemtuzumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- B01AB08 — Reviparin
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5XQ9UBJ16W
- CAS number
- 9041-08-1
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 1996 Nov 15;28(6):1437-43. [Article]
- Klinkhardt U, Breddin HK, Esslinger HU, Haas S, Kalatzis A, Harder S: Interaction between the LMWH reviparin and aspirin in healthy volunteers. Br J Clin Pharmacol. 2000 Apr;49(4):337-41. [Article]
- FDA orphan list [Link]
- External Links
- KEGG Drug
- D03337
- PubChem Substance
- 347910423
- 75960
- Wikipedia
- Reviparin_sodium
- MSDS
- Download (52.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Neoplasms / Venous Thromboembolism 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Parenteral 1750 IU/0.25mL Injection, solution Parenteral 5726 IE Injection, solution Subcutaneous Injection, solution Parenteral 10307 IU/0.6mL Injection, solution Solution Subcutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 50 mg/ml 'MSDS' - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at October 26, 2015 16:53 / Updated at August 13, 2020 07:01